For Health Care Professionals Outside the US
NOW APPROVED IN FL1:
KYMRIAH® (tisagenlecleucel) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
FL
DLBCL1
I Am KYMRIAH
Because
I want to empower my own immune system to fight DLBCL
I need a CAR-T treatment with proven efficacy and a manageable safety profile
I refuse to give up hope
ALL1
I Am KYMRIAH
Because
I want to empower my own immune system to fight ALL
I want a CAR-T treatment with the potential to put my ALL in remission
I have lots of living left to do
Images throughout do not depict actual KYMRIAH patients.
Reference:
- 1.Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2022.
You are now leaving KYMRIAH.com and moving to a site that is for qualified treatment centres only. A log-in and password will be required to access information on this site.
Coming soon
A list of qualified treatment centres near you
This is an international site for KYMRIAH® (tisagenlecleucel) and is intended for health care professionals (HCPs) outside the US.
Welcome to KYMRIAH® (tisagenlecleucel)
You are now leaving KYMRIAH.com and moving to a site that is for qualified treatment centres only. A log-in and password will be required to access information on this site.
You are now leaving KYMRIAH.com and will be redirected to Novartis.com to review the press release.